Cancer Action Newsspacer
Red line

Subscribe to
CancerAction News

Tell a friend

Home Page

Compassionate Use


CancerAction News

Make a Difference

About Us


MNCF Response to Early Approval Proposal
Read it here

NCI's Special Status: Going, Going, Gone?
Read it here

Cancer and Politics
Read it here

Compassionate Use Programs:

5-azacytidine is available for refractory acute myelogenous leukemia

Alimta is available for malignant pleural mesothelioma

Erbitux is available on a limited basis for colorectal cancer.

VSLI is available for refractory pancreatic cancer

Virulizin is available for refractory pancreatic cancer

Marti Nelson Cancer Foundation Response to Drug Approval Proposal

A proposal to approve drugs after "promising" phase 1 clinical trial data has been made by the Abigail Alliance. While MNCF supports early access to experimental cancer therapies, we believe that this access must be based on science, not just hope.  

We all hope for a non-toxic, highly effective cancer treatment that's also cheap and easy to manufacture.   Unhappily, most cancer drugs - even the newer, targeted therapies - have significant risks of toxicity, and marginal efficacy. Patients have the right to expect treatment that works, especially once a drug is approved and being sold by drug companies.

Our concerns as relayed to FDA can be viewed here.

Additional comments to FDA from a group of patient advocates can be seen here.


NCI's Special Status: Going, going, gone?

In the early 1970s, the National Cancer Institute (NCI) was granted special access to the President, bypassing oversight by the National Institutes of Health (NIH).   Since then, NCI's directors have been chosen by the President, and NCI's budget has gone directly to the President.

A recent report by the Institute of Medicine recommended that Congress reconsider NCI's special status. At a joint Senate-House hearing on the report, a former director of NIH said the authority of the NIH Director should be strengthened, in part by revoking the "special privileges" for NCI.

Many in the cancer research community are concerned that NCI's autonomy could be harmed if NCI's status is revoked. Written testimony from the American Association for Cancer Research said, "the provisions of the National Cancer Act must be preserved to ensure that the Director of the NCI has the flexibility and authority to make further inroads against cancer at the earliest possible time."

Read AACR's testimony here.

Read the National Coalition of Cancer Research testimony here.

Read the Institute of Medicine report here.


Cancer and Politics

What does cancer have to do with politics? A lot, according to the American Cancer Society.

Review current cancer politics and check out the ACS Action Network here.


© copyright 2003 | contact | site map | privacy policy/legal